- Home
- NMT vs LIXT Comparison
NMT vs LIXT Comparison
Compare NMT & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMT | LIXT |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 107.6M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMT | LIXT |
|---|---|---|
| Price | $12.78 | $7.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.2K | ★ 542.8K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.11 | $2.45 |
| 52 Week High | $13.70 | $8.38 |
Technical Indicators
Market Signals| Indicator | NMT | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 54.53 |
| Support Level | $11.45 | $6.21 |
| Resistance Level | $13.18 | $7.64 |
| Average True Range (ATR) | 0.17 | 0.84 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 64.97 | 53.35 |
Price Performance
Historical ComparisonAbout NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.